AstraZeneca · 1 day ago
Senior Patent Attorney
AstraZeneca is a global biopharmaceutical company, and they are seeking a Senior Patent Attorney to manage and prosecute an IP portfolio related to assigned client areas. The role involves providing IP advice, establishing IP strategies, and managing external service providers while effectively communicating with R&D clients.
BiopharmaBiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Independently draft and prosecute a IP portfolio (either patents, or trademarks and other non-patent IP, as appropriate) relating to an assigned client area
Provide IP advice to the assigned clients reflecting R&D objectives, and identify and address IP opportunities and risks
Establish and implement IP strategies for the assigned area
Communicate effectively with R&D clients on IP matters
Operate effectively within global IP teams on AZ IP operational or strategic IP issues
Work on IP diligence and other activities in support of SPBD opportunities
Manage external service providers effectively
In Patents, act as an attorney of record for US or EP prosecution
Qualification
Required
Full relevant legal qualification
Strategic thinking
Extensive experience of IP/TM in multiple markets and jurisdictions
Strong written and spoken communication skills in English
Preferred
Experience in the pharmaceutical industry
Experience managing external service providers
Benefits
Short-term incentive bonus opportunity
Equity-based long-term incentive program (salaried roles)
Retirement contribution (hourly roles)
Commission payment eligibility (sales roles)
Qualified retirement program [401(k) plan]
Paid vacation and holidays
Paid leaves
Health benefits including medical, prescription drug, dental, and vision coverage
Company
AstraZeneca
AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. It is a sub-organization of Investor.
Funding
Current Stage
Public CompanyTotal Funding
$5.26B2024-07-30Post Ipo Debt· $1.51B
2023-02-28Post Ipo Debt· $2.25B
2023-02-24Post Ipo Debt· $1.5B
Leadership Team
Recent News
News Powered by Cision
2026-01-08
2026-01-07
Pharma Letter
2026-01-07
Company data provided by crunchbase